Anterix Inc

1. 1

   Election of Directors

   ManagementBoard: FOR

   Elect seven directors nominated by the Board to serve until the 2027 Annual Meeting and until their successors are elected and qualified.

2. 2

   Advisory Vote to Approve Compensation of Our Named Executive Officers

   ManagementBoard: FOR

   Non-binding advisory vote to approve the compensation of the company's named executive officers as disclosed in the Proxy Statement (Say-on-Pay).

   More detail

   This proposal asks stockholders to cast a non-binding advisory vote to approve the company’s disclosed compensation of its named executive officers (NEOs). Management is seeking this approval to reaffirm its compensation philosophy and governance approach—emphasizing a pay-for-performance mix of base salary, short-term cash incentives, and long-term equity awards designed to align executives with stockholder value creation. The Compensation Committee explains its use of a market-informed peer group, an independent compensation consultant, and a short-term incentive plan tied to measurable objectives (customer proceeds, product revenue, free cash flow, regulatory progress, and individual performance) as the primary means to calibrate payouts. Fiscal 2026 design outcomes and payouts are disclosed (e.g., overall STI payout of 42% of target), and management highlights company milestones—such as securing the FCC Report & Order and material spectrum sales—to contextualize pay decisions. The vote is advisory and non-binding, but management states it will consider the outcome in future compensation decisions; prior say-on-pay received 83.9% support in 2025, which management interpreted as strong stockholder endorsement. Supporters should view the proposal as a signal of confidence in the Compensation Committee’s governance processes, alignment mechanisms, and disclosure; critics may point to dilution from equity awards, discretion in certain payouts, or the absolute levels of realized pay. Given the company’s emphasis on retention through equity, its transition in strategy to include spectrum sales and product offerings, and the Compensation Committee’s engagement with major investors, management’s recommendation to vote FOR is grounded in linking pay to specific strategic milestones and independent review processes.

3. 3

   Amendment No. 2 to the 2023 Stock Plan

   ManagementBoard: FOR

   Approve Amendment No. 2 to the Anterix Inc. 2023 Stock Plan to increase the number of shares available for issuance under the plan by 1,000,000 shares.

   More detail

   This management proposal requests shareholder approval to increase the authorized share reserve under the company’s 2023 Stock Plan by 1,000,000 shares (an increase equal to approximately 5.2% of the company’s outstanding shares as of June 11, 2026). Management frames the request as necessary to sustain competitive equity grant practices for hiring, retention, and long-term incentive alignment through anticipated needs (projected sufficiency through the 2028 annual meeting). The Compensation Committee evaluated historical burn rates, dilution, and overhang metrics and considered proxy advisory guidelines before proposing the increase; current Plan metrics (three-year average burn ~3.2%, overhang ~12.4%) are disclosed to justify the size of the request. The Plan includes multiple governance protections — no evergreen provision, no automatic single-trigger acceleration on change in control, repricing only with shareholder approval, minimum vesting periods, limits on share recycling, non-in-the-money grant restrictions, and independent administration by the Compensation Committee — which management highlights to mitigate shareholder dilution risk. Supporters of the amendment will note the company’s growth initiatives (FCC Report & Order, product launches, and spectrum sales) and the need to preserve equity as a cost-effective retention tool; opponents will focus on the dilutionary impact and the potential effect on per-share economics. The Board recommends FOR, arguing that failure to secure additional shares could force the company to rely more heavily on cash incentives (pressuring liquidity) or impair its ability to hire and retain key talent. Given the transparency on metrics, explicit 1.0M share increase amount, and the Plan’s anti-dilution and governance features, the proposal presents a trade-off between measured dilution and preserving the company’s primary long-term incentive lever for management and employees.

4. 4

   Advisory Vote on the Frequency of Future Advisory Votes to Approve NEO Compensation

   ManagementBoard: FOR

   Advisory (non-binding) vote to indicate whether stockholders prefer future advisory votes on NEO compensation to be held every one, two, or three years; the Board recommends a frequency of one year.

   More detail

   This advisory proposal asks stockholders to indicate their preferred frequency (every one, two, or three years) for future non-binding say-on-pay votes. The Board recommends an annual (one-year) frequency, arguing that yearly advisory votes provide the most timely and direct feedback loop between shareholders and the Board/Compensation Committee regarding executive pay decisions. An annual cadence enables quicker stockholder response to compensation program changes and evolving corporate strategy, which management views as important given the company’s recent strategic evolution (spectrum monetization, TowerX, CatalyX). The counterargument for less frequent votes is that two- or three-year cycles reduce voting fatigue and allow multi-year incentive plans sufficient time to run and be evaluated against longer-term performance outcomes. Because this vote is advisory and non-binding, the Board retains discretion and may consider stockholder preferences alongside other factors, including engagement outcomes and the company’s business rhythm. Institutional investors sometimes prefer annual votes for governance responsiveness, while some proxy advisors may be neutral; the Board’s stated recommendation reflects a governance posture favoring ongoing engagement. Stockholders should weigh the trade-off between responsiveness and the administrative and evaluative benefits of multi-year cycles when expressing a preference.

5. 5

   Ratification of Appointment of Independent Registered Public Accounting Firm

   ManagementBoard: FOR

   Ratify the appointment of Deloitte & Touche LLP as the company’s independent registered public accounting firm for the fiscal year ending March 31, 2027.

6. 6

   Other Business

   Management

   Transact such other business properly brought before the meeting and at any adjournment or postponement thereof.

   More detail

   This catch-all item authorizes consideration of any other matters properly presented at the Annual Meeting. It is standard boilerplate that preserves the meeting’s ability to address unforeseen or procedural items that meet legal notice and procedural requirements. Typically, such matters are rare and, if presented, may include ministerial corporate housekeeping items or, less commonly, substantive proposals that arise after proxy materials were finalized. Proxies submitted by management are generally authorized to vote on these items at their discretion, subject to any instructions from the shareholder; however, management has stated it will not vote in favor of director nominees from whom authority is withheld. Because there is no discrete substantive proposal disclosed in advance, shareholders cannot meaningfully evaluate potential future items; stockholders concerned about material late-filed items should monitor meeting notices and disclosures. From a governance perspective, this item imposes minimal direct economic effect but preserves corporate flexibility to conclude the meeting efficiently and to respond to procedural developments that might arise during the meeting.

Upcoming shareholder meetings at Anterix Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.

When is the Anterix Inc 2026 annual meeting?

Anterix Inc (ATEX) holds its 2026 annual shareholder meeting on Tuesday, August 4, 2026.

What is the record date for the Anterix Inc 2026 meeting?

The record date for the Anterix Inc 2026 meeting is Thursday, June 11, 2026. Shareholders of record on or before that date are eligible to vote.

Who are the director nominees for Anterix Inc's 2026 meeting?

The board is presenting 7 director nominees at the Anterix Inc 2026 meeting, listed with their independence status and background.

What proposals will shareholders vote on at the Anterix Inc 2026 meeting?

Shareholders will vote on 6 proposals at the Anterix Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.